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Transcriptional Alterations in Hereditary and Sporadic
Nonfunctioning Pancreatic Neuroendocrine Tumors
According to Genotype
Xavier M. Keutgen, MD 1,2; Suresh Kumar, PhD1; Sudheer Gara, PhD1; Myriem Boufraqech, PhD1; Sunita Agarwal, MD3;
Ralph H. Hruban, MD4; Naris Nilubol, MD1; Martha Quezado, MD5; Richard Finney, PhD6; Maggie Cam, PhD6; and
Electron Kebebew, MD 1,7
BACKGROUND: Nonfunctioning pancreatic neuroendocrine tumors (NFPanNETs) may be sporadic or inherited because of germline
mutations associated with von Hippel-Lindau disease (VHL) or multiple endocrine neoplasia type 1 (MEN1). The clinical behavior of
NFPanNETs is difficult to predict, even in tumors of the same stage and grade. The authors analyzed genotype-specific patterns of
transcriptional messenger RNA (mRNA) levels of NFPanNETs to understand the molecular features that determine PanNET pheno-
type. METHODS: Thirty-two samples were included for genome-wide mRNA gene expression analysis (9 VHL-associated, 10 MEN1-
associated, and 9 sporadic NFPanNETs and 4 purified normal islet cell [NIC] samples). Validation of genes was performed by real-
time polymerase chain reaction analysis and immunohistochemistry. Gene expression profiles were analyzed by tumor genotype, and
pathway analysis was curated. RESULTS: Consensus clustering of mRNA expression revealed separate clustering of NICs, VHL-
associated NFPanNETs, and MEN1-associated NFPanNETs; whereas some sporadic tumors clustered with MEN1. Four of 5 MEN1-like
sporadic PanNET subtypes had loss of heterozygosity at the MEN1 gene locus. Pathway analysis demonstrated subtype-specific path-
way activation, comprising angiogenesis and immune response in VHL; neuronal development in MEN1; protein ubiquitination in the
new MEN1/sporadic subtype; and cytokinesis and cilium/microtubule development in sporadic NFPanNETs. Among many genes,
platelet-derived growth factor receptor b (PDGFRB), lymphoid enhancer-binding factor-1 (Lef-1), cyclin-dependent kinase 4 (CDK4),
and CDK6 were upregulated in VHL or MEN1 NFPanNETs, providing potential subtype-specific treatment targets. CONCLUSIONS:
Distinct mRNA expression patterns were identified in sporadic-associated, VHL-associated, and MEN1-associated NFPanNETs. The
current results uncover new pathways involved in NFPanNETs that are subtype-specific and provide potential new diagnostic or
therapeutic targets based on tumor subtype. Cancer 2017;000:000-000. VC 2017 American Cancer Society.
KEYWORDS: multiple endocrine neoplasia type 1 (MEN1), neuroendocrine, pancreas, sporadic, von Hippel-Lindau syndrome (VHL).
INTRODUCTION
Pancreatic neuroendocrine tumors (PanNETs) are characterized by a distinctive histology and evidence of neuroendocrine
differentiation. In the United States, it is estimated that 3 to 5 cases per 100,000 inhabitants occur annually, and the inci-
dence of these neoplasms continues to increase.1 PanNETs can be divided into functioning tumors (produce clinical find-
ings related to excess hormone production) and nonfunctioning tumors (NFPanNETs), and the latter are much more
prevalent. Although functioning PanNETs require treatment because of the morbidity and mortality caused by excess hor-
mone production, small NFPanNETs do not always require treatment.
PanNETs can occur sporadically or in inherited cancer syndromes, such as von Hippel-Lindau syndrome (VHL),
multiple endocrine neoplasia type 1 (MEN1), neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC), and
Cowden syndrome (CS).2-6 From 9% to 17% of patients with VHL and from 30% to 80% of patients with MEN1
develop PanNETs during their lifetime.4,7 By contrast, the penetrance of PanNETs in NF1, TSC, and CS is lower; and
these latter syndromes are relatively rare.
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Hereditary PanNETs often behave less aggressively
than their sporadic counterparts, but the reasons underly-
ing these differences in clinical behavior are not well
defined.4,8 The clinical management of hereditary Pan-
NETs is complicated by the presence of multiple lesions
and the risks associated with multiple surgeries. Current
recommendations for resection of hereditary PanNETs
are mostly based on the risk of metastatic disease, using
tumor growth and size as surrogate markers for aggressive-
ness.4,7 However, these criteria are imperfect and do not
accurately predict the metastatic potential and/or aggres-
sive behavior of all patients with PanNETs and VHL or
MEN1.7,9-12
The genes responsible for the major inherited pre-
disposition syndromes (VHL, MEN1) are known, and
large numbers of PanNETs have been sequenced.13
Sequencing of sporadic PanNETs have identified a multi-
tude of somatic mutations, including MEN1 in up to
44% of cases and death domain-associated protein
(DAXX), a-thalassemia X-linked intellectual disability
syndrome (ATRX), phosphatase and tensin homolog
(PTEN), TSC2, and phosphatidylinositol 4,5-bisphos-
phate 3-kinase catalytic subunit a (PIK3CA), as well as
mutations or promoter hypermethylation in VHL in up
to 25% of patients.13-16 Despite these advances, the tran-
scriptional changes and downstream pathway activations
promoting early tumorigenesis are largely unknown but
could be useful to identify targets for diagnosis and treat-
ment of both hereditary and sporadic PanNETs.4,7,17
In this study, we sought to investigate transcriptional
levels of messenger RNA (mRNA) by DNA microarray
from hereditary (MEN1, VHL) and sporadic, early stage
NFPanNETs to discover dysregulated pathways associated
with tumorigenesis and to elucidate possible transcriptional
targets that may be deregulated across all genotypes or in
just 1 particular genotype of NFPanNETs.
MATERIAL AND METHODS
Sample Selection
Thirty NFPanNETs and 6 normal islet cell (NIC) sam-
ples were initially selected for this study. All tumors were
chosen to be early stage NFPanNETs to account for stage
mismatch when comparing genotypes and to reflect
actual, common presentations of NFPanNETs in patients
with MEN1 and VHL. Thirty-two samples were ulti-
mately included in this analysis; 1 sporadic sample was
excluded because of advanced stage, including metastatic
disease; and 1 VHL and 2 NIC samples were excluded
because of poor RNA quality. The final analyzed group
comprised 10 NFPanNETs from patients with MEN1, 9
NFPanNETs from patients with VHL, 9 sporadic
NFPanNETs, and 4 purified NIC samples (Fig. 1). All
patients who had MEN1 and VHL had a germline muta-
tion in the respective syndromal gene. The functional sta-
tus of the tumor was determined by clinical features and
symptoms and through biochemical testing (fasting gas-
trin, insulin, vasoactive intestinal peptide, somatostatin,
and glucagon). Immunohistochemistry staining of
paraffin-embedded tumor slides for gastrin and insulin also
was performed in MEN1-associated NFPanNETs. Tissues
were obtained from pancreatectomies (pancreaticoduode-
nectomy or distal pancreatectomy specimens) or NFPan-
NET enucleations performed at our hospital or at the
participating institution between 2010 and 2014. These
samples were fresh-frozen after procurement and stored at
280 8C. Serial tissue sections were used for RNA extrac-
tion, stained with hematoxylin and eosin, and reviewed by
a pathologist to confirm the diagnosis and ensure that the
section had>80% neoplastic nuclei content.
Primary human pancreatic islets of Langerhans were
purchased from the Division of Transplantation Surgery
at the University of Alabama at Birmingham. Pancreata
were recovered, with informed consent, from cadaveric
donors after in situ vascular perfusion with University of
Wisconsin solution at 4 8C as part of a multiorgan pro-
curement. Pancreata were immediately transported to the
islet isolation laboratory for processing. Islets were iso-
lated using a semiautomated method and were purified
using the Cobe 2991 cell processor (Gambro BCT, Lake-
wood, CO). The number of islets within each size class
was converted to the standard number of islets measuring
150 lm in greatest dimension (equal in volume to the
sample). Purity was assessed by comparing the relative
quantity of dithiozone-stained endocrine tissue with that
of unstained exocrine tissue. Only islet isolations with
>90% viability and>60% purity were used.
This study was approved by the Office for Human
Research Protections at the Department of Health and
Human Services. Patient information was collected pro-
spectively under an Institutional Review Board-approved
protocol at the National Institutes of Health (Bethesda,
MD) after obtaining written informed consent.
RNA Extraction
Total RNA was extracted from approximately 20 to
30 mg of tissue using the Total RNA Purification Kit
(17200; Norgen Biotek Corporation, Thorold, ON,
Canada) and from purified NICs using the AllPrep
DNA/RNA Mini Kit (catalog no. 80204; Qiagen,
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Hilden, Germany). Total RNA yield was assessed using
NanoDrop (NanoDrop Technologies, Wilmington, DE)
and the Bioanalyzer 2100 and RNA 6000 Nano/Pico
LabChip (Agilent Technologies, Palo Alto, CA). Comple-
mentary DNA (cDNA) was obtained by reverse transcrip-
tion using the Murine Leukemia Virus Reverse




RNA quantity and quality were measured using the
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies). RNA integrity was assessed by standard
denaturing agarose gel electrophoresis.
DNA microarray
The Whole Human Genome Oligo Microarray (Agilent
Technologies) provides a broad view that represents all
known genes and transcripts in the human genome.
Sequences were compiled from a broad-source survey and
then verified and optimized by alignment to the assem-
bled human genome.
RNA labeling and array hybridization
Sample labeling and array hybridization were performed
according to the Agilent One-Color Microarray-Based
Gene Expression Analysis protocol (Agilent Technolo-
gies). Briefly, total RNA from each sample was linearly
amplified and labeled with indocarbocyanine (Cy3)-uri-
dine diphosphate. The labeled complementary RNAs
(cRNAs) were purified using the RNeasy Mini Kit
(Qiagen). The concentration and specific activity of the
labeled cRNAs (pmol Cy3/lg cRNA) were measured
using the NanoDrop ND-1000 spectrophotometer. One
microgram of each labeled cRNA was fragmented by
adding 11 lL 10 3 blocking agent and 2.2 lL 25 3
fragmentation buffer; heating at 60 8C for 30 minutes;
and finally adding 55 lL 2 3 gene expression hybridiza-
tion buffer to dilute the labeled cRNA. One hundred
microliters of hybridization solution was dispensed into
the gasket slide and assembled to the gene expression
microarray slide. The slides were incubated for 17 hours
at 65 8C in an Agilent hybridization oven (Agilent Tech-
nologies). The hybridized arrays were then washed, fixed,
and scanned using the Agilent DNA Microarray Scanner
(part number G2505C; Agilent Technologies).
Data analysis
Agilent Feature Extraction software (version 11.0.1.1;
Agilent Technologies) was used to analyze the acquired
array images. Quantile normalization and subsequent
data processing were performed using GeneSpring GX
software (version 12.1; Agilent Technologies). Raw data
were normalized using quantile normalization, followed
by cyclic loess using the Bioconductor limma package
(version 3.30.11; Bioconductor Core Team, Roswell Park
Cancer Institute, Buffalo, NY).18 Consensus clustering
was performed on all gene expression data using the Bio-
conductor package ConsensusClusterPlus (version 1.38;
Bioconductor Core Team).19 We evaluated from k 5 2 to
6 clusters and selected k 5 5 clusters that had the
Figure 1. (A) This is a breakdown of nonfunctioning pancre-
atic neuroendocrine tumors (NFPanNETs) and normal islet
cell samples analyzed by complementary DNA microarray. G
indicates grade; LNM, lymph node metastases; MEN-1, multi-
ple endocrine neoplasia type 1; VHL, von Hippel-Lindau dis-
ease. (B) Unsupervised hierarchical clustering of microarray
data defines 5 distinct groups. (C) This is a representative
image of loss of heterozygosity for the MEN1 gene in a spo-
radic NFPanNET using the microsatellite marker DS11S956
(red box). T indicates tumor; N, normal.
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maximum area under the curve in the consensus cumula-
tive distribution function plot. Subtype-unique expressed
genes were identified by selecting genes, wherein the 90%
confidence interval (CI) within each subtype exceeded the
90% CI of expression for all other subtypes, including
normal. Subtype-unique gene lists were subjected to
gene category enrichment analysis using the Fisher exact
test on various publicly available databases, including
Gene Ontology (GO) (https://www.geneontology.org,
Accessed May 1, 2017), Kyoto Encyclopedia of Genes
and Genomes (KEGG) (https://www.genome.jp/kegg/
pathway.html, Accessed May 1, 2017), Protein Analysis
Through Evolutionary Relationships (PANTHER)
(https://www.pantherdb.org, Accessed May 1, 2017), PC
REACTOME (https://www.reactome.org, Accessed May
1, 2017), Inter Partes Review (IPR), PC NCI NATURE
(http://pid.nci.nih.gov, Accessed May 1, 2017), and the
National Center for Biotechnology Information (https://
www.ncbi.nlm.nih.gov, Accessed May 1, 2017) database.
Group comparisons of categorical variables were per-
formed using the Pearson chi-square test or the Fisher exact
probability test, and the comparison of continuous varia-
bles was performed with 2-tailed t tests or Wilcoxon rank
tests. All P values were considered statistically significant if
P was less than .05. GraphPad Prism (GraphPad Software
Inc, La Jolla, CA) was used for statistical analyses.
Ion Torrent Next-Generation Sequencing
Analysis
Primers for the genes involved in NFPanNETs (MEN1,
ATRX, DAXX, and VHL) were designed for a custom
Ampliseq panel using Life Technologies software (Ion
Ampliseq Designer; Thermo Fisher Scientific). Ampliseq
libraries were prepared from DNA samples extracted from
NFPanNET samples using the RNA/DNA/Protein Puri-
fication Plus Kit (47700; Norgen Biotek Corporation).
DNA sample concentrations were determined using
NanoDrop (ND8000; Thermo Fisher Scientific). Final
sample qualification and quantification were established
with Picogreen analysis (standard curve assay) on a Molec-
ular Devices Gemini XPS Plate Reader and Softmax Pro
Software (Molecular Devices, Sunnyvale, CA). All sam-
ples and controls were run in triplicate.
Ampliseq libraries were prepared for each DNA sam-
ple. To create libraries, each DNA sample was first ampli-
fied according to the manufacturer’s protocol. Each library
was then assigned a unique, barcode-adapter sequence and
ligated onto the libraries. The final libraries were qualified
and quantified using Life Technologies’ Ion Library Quan-
titation Kit (item 4468802; Thermo Fisher Scientific).
Libraries were then cycled and analyzed on an ABI PRISM
7900HT Sequence Detection System (Thermo Fisher
Scientific). By using the quantification values from the
real-time polymerase chain reaction (PCR) analysis, all
libraries were then normalized with 1X low Tris-
ethylenediaminetetraacetic acid buffer to either 50 or
100 pMol to prepare for emulsion PCR. Libraries were
then combined into pools of 9 for a total of 4 pools. Com-
bined with an Ion 318 chip, roughly 300X coverage per
amplicon was achieved. The clonal emulsion amplification
of Ampliseq libraries was sequenced on the Ion Torrent
Personal Genome Machine (PGM) platform using the Life
Technologies OneTouch 2 (OT2) system (Thermo Fisher
Scientific). The OT2 system is automated and, when used
in conjunction with the Enrichment Station, generates
template-positive, Ion PGM Template OT2 200 Ion
Sphere Particles for semiconductor sequencing. All analyses
and data quality controls were completed using the Life
Technologies Ion Torrent Suite (version 5.0.4).
Real-Time PCR
Gene expression levels were measured using specific pri-
mers and probes. Briefly, 500 to 1000 ng of total RNA
was reverse transcribed using a High-Capacity Reverse
Transcription cDNA Kit (catalog no. 4374967; Applied
Biosystems, Thermo Fisher Scientific), and the resulting
cDNA was diluted and amplified according to the manu-
facturer’s instructions. Glyceraldehyde 3-phosphate dehy-
drogenase was used as an endogenous control. Gene
expression levels were calculated using SDS 2.3 software
(Applied Biosystems, Thermo Fisher Scientific).
Immunohistochemistry
Sections were deparaffinized and rehydrated, and antigen
retrieval was performed with citrate buffer in a water bath
at 120 8C. The sections were incubated with the anti-
platelet-derived growth factor receptor b (anti-PDGFRB)
antibody (1:100 dilution; Abcam, Cambridge, UK) over-
night at 4 8C, followed by incubation with a biotinylated
secondary antibody for 1 hour at room temperature. The
slides were developed with diaminobenzidine (EnVision
Kit System Horseradish Peroxidase [diaminobenzidine];
Dako, Carpinteria, CA) and counterstained with hema-
toxylin. Then, the slides were scanned at 320 magnifica-
tion using a ScanScope XT digital slide scanner (Aperio
Technologies, Leica Biosystems Nussloch, GmbH, Nus-
sloch, Germany) to create whole-slide image data files at a
resolution of 0.5 mm/pixel and viewed using ImageScope
software (Aperio Technologies). All immunohistochemis-
try slides were reviewed and scored by a pathologist who
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was unaware of the sample groups. Tumor staining
in> 50% of each slide was considered positive. Positive
staining was graded as weakly positive (1), moderately
positive (11), or strongly positive (111).
DNA Extraction and Loss of Heterozygosity
Analysis
DNA was extracted from tissue and leukocytes using the
Qiagen Blood and Cell Culture DNA Kit (Qiagen) fol-
lowing the manufacturer’s protocol. Primers for the poly-
morphic microsatellite markers D11S956, D11S4939,
D11S4946, PYGM, and D11S987 were identical to those
published previously.20 PCR was performed in a total vol-
ume of 100 mL containing 30 pmol of each primer, 2.5 U
Taq polymerase (Perkin Elmer, Foster City, CA), and
100 to 400 ng DNA. The cycler program was as follows:
initial denaturation at 95 8C for 5 minutes; 30 cycles at
55 8C for 1.5 minutes, 72 8C for 1.5 minutes, and 94 8C
for 1.5 minutes; and a final extension at 72 8C for 5
minutes. Primer sequences for D11S956, D11S4939,
D11S4946, PYGM (glycogen phosphorylase, muscle
associated), and D11S987 PCR conditions were used as
published previously with minor modifications.21
The PCR product was purified with chloroform.
Purified PCR product was dried in a SpeedVac
(Thermo Fisher Scientific), redissolved in 10 lL formam-
ide and 10 lL H2O, and loaded onto a 6% Tris-borate-
ethylenediaminetetraacetic acid polyacrylamide gel.
Electrophoresis was performed at 150 V for 90 minutes.
After staining with ethidium bromide for 10 minutes, the
amplification products were observed on an ultraviolet
transilluminator. Loss of heterozygosity (LOH) was deter-




Twenty-eight patient samples with NFPanNETs were
selected according to the criteria described above (see Mate-
rials and Methods). Fifty percent of samples were World
Health Organization grade 1 tumors, and 50% were World
Health Organization grade 2 tumors in each subgroup
(VHL, MEN1, and sporadic). Two patients in the VHL
group and 1 patient in the MEN1 and sporadic group had
lymph node metastases at the time of diagnosis. There were
no statistically significant differences when comparing clin-
ical and histopathologic characteristics between subgroups,
except for tumor size, which was significantly larger in spo-
radic tumors compared with VHL (P 5 .01) and MEN1
NFPanNET samples (P 5 .002) (Fig. 1A, Supporting
Table 1; see online supporting information).
Consensus cluster analysis
Consensus cluster analysis of gene expression levels revealed
that NICs and VHL tumor samples clustered in separate
groups, whereas sporadic and MEN1 samples clustered
alone or in a fifth MEN1/sporadic group (Fig. 1B). We did
not observed any clustering according to patient demo-
graphic or histopathologic data or MEN1 mutation locus
between the MEN1, sporadic, and MEN1/sporadic
groups. Ion Torrent next-generation sequencing analysis
identified 2 nonsynonymous and 1 stop-gain exonic muta-
tions in MEN1 in 3 separate sporadic NFPanNET samples
that clustered with the MEN1 group; and LOH analysis
revealed LOH at the MEN1 locus in 4 of 5 samples (Fig.
1C), possibly explaining why these samples clustered into
the fifth group on unsupervised cluster analysis and con-
firming the common occurrence of MEN1 mutations in
sporadic PanNETs, as previously reported.13 Because it
was reported previously that the transcription/chromatin
remodeling genes DAXX (death-domain-associated pro-
tein) and ATRX were commonly mutated in NFPan-
NETs,13 we evaluated whether somatic mutation in these
genes influenced transcriptional clustering. Four ATRX
mutations no DAXX mutations were identified in MEN1
and sporadic NFPanNET samples. Two nonsynonymous
exonic ATRX mutations were identified in the sporadic
only group, including 1 nonsynonymous exonic mutation
in the MEN1/sporadic group and 1 nonsynonymous
exonic mutation in the MEN1 group, suggesting that
ATRX and DAXX mutations were not associated with the
transcriptional clustering of tumor samples.
Differentially expressed genes in NFPanNETs
according to genotype
A limited list of the most highly upregulated genes in
NFPanNETs according to subtype is summarized in Sup-
porting Figure 1 (see online supporting information).
The most commonly upregulated genes in all 3 subtypes
compared with NICs was Kruppel-like factor 12
(KLF12). KLF12 is a developmentally regulated transcrip-
tion factor that has demonstrated the ability to promote
cell-cycle transition and regulate anoikis through S-phase
and, thus, regulate cell proliferation. It was the gene with
the highest predicted connectivity in a recent study evalu-
ating integrated mRNA-microRNA analysis in Pan-
NETs.22,23 We randomly selected 2 overexpressed genes
(KLF-12 and cyclin D1 binding protein 1 [CCNDBP1]),
and 1 under expressed gene (matrix metallopeptidase
Genotype-Specific Alterations in PanNET/Keutgen et al
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1 [MMP1]) for validation by reverse transcriptase-
quantitative PCR (Supporting Fig. 2; see online support-
ing information).
We also observed genotype-specific differences in
gene expression when we compared 1 subgroup with all
others (Supporting Fig. 1; see online supporting informa-
tion). In the VHL group, we observed overexpression of
the neurogenic locus notch homolog protein 3 mRNA
(Notch 3), which reportedly is upregulated in the vascular
endothelium of VHL-associated central nervous system
hemangioblastomas, as well as overexpression of insulin-
like growth factor 2 (IGF-2) mRNA, which reportedly
is upregulated in the PanNET cell lines BON-1 and
QPG-1.24,25 In the MEN1 group, it was common to
observe the overexpression of ryanodine receptor 3
(RYR3) mRNA, which reportedly plays an important role
in pancreatic b-cell insulin secretion.26 It is noteworthy
that fibroblast growth factor 13 (FGF-13), which has
been associated with aggressive tumor behavior and
shorter disease-free survival, was significantly upregulated
in the sporadic and MEN1 subgroups only.27
GO Pathway Analysis
GO pathway analysis yielded subtype-specific pathway
alterations. Among the 20 most upregulated pathways in
VHL-associated NFPanNETs, those relating to angiogen-
esis and immune response were identified as highly upre-
gulated (Fig. 2). The pathways involved in cilium and
microtubule formation, both of which are part of the cell’s
spindle-cell apparatus and are crucial to cell division, were
upregulated in sporadic NFPanNETs, which could
explain the reported aggressive behavior and rapid growth
of sporadic tumors compared with their hereditary coun-
terparts (Fig. 3).28 Gene enrichment in pathways com-
prising ion channel activity and neuron development,
both of which reportedly are upregulated in PanNETs,
were most prevalent in MEN1-associated NFPanNETs
only (Fig. 4).29 Protein ubiquitination pathways, which
reportedly are involved in blockade of the proteasome-
degradation machinery and thus enhance glucose-
stimulated insulin secretion and promote certain gene-
expression patterns, were upregulated most in the MEN1/
sporadic NFPanNET subtype (Fig. 5).30
Validation of selected genotype-specific mRNA
targets
To further validate our microarray analysis, we compared
our expression data with results from a previous study that
compared mRNA expression in VHL PanNETs with that
in sporadic PanNETs.31 Nineteen genes previously
Figure 2. (A) Messenger RNA enrichment analysis (GO, Gene Ontology [GO]) is illustrated for the top 20 upregulated pathways
in von Hippel-Lindau disease (VHL) versus other nonfunctioning pancreatic neuroendocrine tumors and normal islet cells. (B)
There is a predominance of genes involved in angiogenesis and immune response (yellow box). MEN1 indicates multiple endo-
crine neoplasia type 1; VHL, von Hippel-Lindau disease.
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reported as upregulated and 3 genes previously reported
as downregulated had similar expression levels in our data
set when comparing VHL versus sporadic NFPanNETs
(Supporting Fig. 3; see online supporting information).
Next, we selected a small subset of genotype-
specific genes for validation based on their potential
translational relevance because of their ability to be tar-
geted for treatment. We observed that PDGFRB was
upregulated (>2-fold) in VHL PanNETs, and this was
confirmed by TaqMan reverse transcriptase-PCR
(Fig. 6B,C). Immunohistochemical analysis demon-
strated that PDGFRB was significantly overexpressed
Figure 3. (A) Messenger RNA enrichment analysis (REACTOME and Gene Ontology [GO]) is illustrated for the top 20 upregu-
lated pathways in sporadic versus other nonfunctioning pancreatic neuroendocrine tumors and normal islet cells. (B) There is a
predominance of genes involved in cilium and microtubule processes (yellow box). MEN1 indicates multiple endocrine neoplasia
type 1; VHL, von Hippel-Lindau disease.
Figure 4. (A) Messenger RNA enrichment analysis (Gene Ontology [GO]) is illustrated for the top 20 upregulated pathways in
multiple endocrine neoplasia type 1 (MEN1) versus other nonfunctioning pancreatic neuroendocrine tumors and normal islet cells.
(B) There is a predominance of genes involved in ion channel activity and neural development (yellow box). VHL indicates von
Hippel-Lindau disease.
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in VHL NFPanNETs versus MEN1 and sporadic
NFPanNETs (P 5 .03); however, we noted that mostly
the tumor stroma, and not the tumor cells, stained
positive in VHL samples (Fig. 6A). To test the
hypothesis that VHL NFPanNETs have greater stromal
content than other PanNETs, we used the Estimation
of Stromal and Immune Cells in Malignant Tumors
Using Expression Data (ESTIMATE) gene signature
model as previously described.32 We observed signifi-
cant overexpression of the 141 stromal gene signature
panel in VHL tumors compared with the MEN1 and
sporadic NFPanNET genotype (P< .05) (Fig. 6D).
Additional genes that were upregulated on gene
expression analysis and validated by reverse transcriptase-
PCR included overexpression of the transcription factor
lymphoid enhancer-binding factor-1 (Lef-1) in VHL
NFPanNETs and overexpression of cyclin-dependent
kinase 4 (CDK4) and CDK6 in MEN1 NFPanNETs
(Fig. 6E,G,H). The tumor-suppressor CDKN1B also was
downregulated in MEN1 NFPanNETs compared with
other genotypes (Fig. 6F). CDK4 and CDK6 gene expres-
sion analysis according to groups from hierarchical clus-
tering indicated that CDK4 levels were higher in the
MEN1 and MEN1/sporadic genotypes compared with
the sporadic, non-MEN1 genotype, although the differ-
ence was not statistically significant (Supporting Fig. 4;
see online supporting information).
Next, we evaluated the differentially expressed genes
in an independent cohort of previously analyzed Pan-
NETs using publicly available microarray data from the
National Center for Biotechnology Information Gene
Expression Omnibus (GEO) repository (https://www.
ncbi.nlm.nih.gov/geo, Accessed May 1, 2017). In a previ-
ously published study comparing cDNA microarray data
from 56 NFPanNETs with data from pancreatic NICs,33
we randomly selected 15 NFPanNET samples from this
microarray data set for cross-validation and observed that
CDK4 expression was the highest among all samples
(average, 6.9-fold vs pancreatic NICs) and Notch3 expres-
sion was lowest (average, 3.8-fold vs pancreatic NICs).
Lef-1, CDK6, PDGFRB, and IGF2 also were overex-
pressed compared with their expression in pancreatic
NICs (fold change: range, 3.8-fold to 4.9-fold).
DISCUSSION
The molecular mechanisms that give rise to NFPanNETs
are complex and are not completely understood. Inacti-
vating germline or somatic mutations in tumor-
suppressor genes like VHL or MEN1 contribute signifi-
cantly to the tumorigenesis of NFPanNETs. However,
additional events involved in proliferative and antiapop-
totic signals and, in certain cases, evasion of the immune
system and modification in the tumor microenvironment,
are important in the initiation and/or progression of
NFPanNETs. Proliferative and antiapoptotic signals are
probably genotype-specific, as demonstrated in the cur-
rent study, and arise from aberrant regulation of signal-
transduction/growth (the phosphoinositide 3-kinase/
protein kinase B [PI3K/AKT]), hypoxia/angiogenesis
(VHL mutation), cell-cycle progression (down-regulation
of CDK inhibitors), and/or genome-stabilization pathways.
Figure 5. (A) Messenger RNA enrichment analysis (Gene Ontology [GO]) is illustrated for the top 20 upregulated pathways in
multiple endocrine neoplasia type 1(MEN1)/sporadic versus other nonfunctioning pancreatic neuroendocrine tumors and normal
islet cells. (B) There is a predominance of genes involved in protein ubiquitination (yellow box). VHL indicates von Hippel-Lindau
disease.
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Previous studies investigating transcriptional altera-
tions in PanNETs have mostly focused on comparing
benign versus malignant PanNETs, defining these cate-
gories according to the absence or presence of metastatic
disease.27,29,34,35 Most of those studies also comprised
relatively small samples sizes and/or heterogenous
PanNET cohorts, including functioning and nonfunc-
tioning tumors, or used normal pancreatic tissues as a
control.29,34,35 The objective of our current analysis was
to identify transcriptional alterations based on tumor
genotype. Indeed, we discovered a subset of sporadic
tumors that cluster with MEN1 tumors, revealing an
additional way to classify tumors according to gene-
expression phenotypes. In addition, our sample selection
was purposely designed to be as homogenous as possible
to uncover differences in pathways according to tumor
Figure 6. (A) Immunohistochemical analysis of platelet-derived growth factor receptor b (PDGFRB) in von Hippel-Lindau disease
(VHL), multiple endocrine neoplasia type 1(MEN1), and sporadic pancreatic neuroectodermal tumors (PanNETs) reveals signifi-
cantly increased expression in VHL PanNET cells (P< .05). (B) Reverse transcriptase-quantitative polymerase chain reaction (RT-
qPCR) analysis of PDGFRB expression confirms the microarray analysis and indicates significantly increased messenger RNA
(mRNA) levels in the initial cohort. (C) Independent RT-qPCR validation of PDGFRB expression is illustrated in a separate set of
19 nonfunctioning PanNETs (NFPanNETs) and 4 normal islet cell samples (P< .05). (D). The “Estimation of Stromal and Immune
Cells in Malignant Tumors Using Expression Data” (ESTIMATE) gene signature model confirms an increased stromal signature in
VHL PanNETs (yellow box). (E-H) RT-qPCR expression analysis reveals (E) overexpression of the transcription factor lymphoid
enhancer-binding factor-1 (LEF1) in VHL NFPanNETs compared with sporadic and MEN1-associated NFPanNETs; (F) overexpres-
sion of the cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor 2C (CDKN2C) in MEN1-associated NFPanNETs compared with spo-
radic (P 5.06) and VHL-associated (P 5.02) NFPanNETs; (G) overexpression of CDK4 in MEN1-associated NFPanNETs compared
with sporadic NFPanNETs (P 5.0009) and normal islet cells (P 5.05); and (H) overexpression of CDK6 in MEN1-associated
NFPanNETs compared with sporadic NFPanNETs (P 5.05). Asterisk indicates statistically significant (p<.05).
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genotype rather than differences in stage-dependent
tumor biology. We did not observe any statistically sig-
nificant differential gene expression across tumor grades
or samples with lymph node metastases. This is likely
because most tumors had a low Ki-67 index within the
grade 2 group, and the rate of lymph node metastases
was too low in each of the subgroup to perform an ade-
quately powered analysis. However, we believe that, by
choosing a homogenous group of stage I and II NFPan-
NETs for each genotype, we uncovered transcriptional
alterations that may occur at earlier stages in NFPanNET
tumorigenesis.
Mutations in the tumor-suppressor VHL gene cause
E3 ubiquitin ligase inactivity and subsequent upregula-
tion of the hypoxia-inducible factor 1a (HIF1a) protein
by inhibiting its degradation.17 HIF1a is a transcription
factor that induces the expression of several angiogenesis-
related factor, as demonstrated in the current study, but
also induces the expression of genes that promote macro-
phage and neutrophil energy generation, inflammatory
and bactericidal activities, and cell survival.17,36 The exact
mechanisms by which VHL-mutated cells influence the
immune system response are complex and poorly under-
stood. However, some data suggest that the proangiogene-
sis state of VHL-mutated cells is central for immune
response evasion of tumor cells. It has been demonstrated
that the high proangiogenic status of clear cell renal cell
cancers (RCCs), which commonly have VHL mutations,
is associated with an accumulation of regulatory T cells
and myeloid-derived suppressor cells in the local tumor
microenvironment, particularly in the tumor invasion
zone.37 This might allow cells to evade immune surveil-
lance, thereby promoting disease progression. Another
recent study in RCC also has suggested that VHL-
dependent alterations of the RCC secretome modulate T-
cell activation by negatively interfering with T-cell prolif-
eration and cytokine secretion.29 Vascular endothelial
growth factor (VEGF) overexpression has also been
directly linked to immunosuppression by inhibiting the
maturation of dendritic cells through a nuclear factor jB-
dependent pathway (mediated by VEGFR-1 signaling)
and to promoting the induction of regulatory CD4-posi-
tive/CD25-positive T cells within the tumor microenvi-
ronment.38 Finally, increased adenosine concentrations
observed in VHL-mutated cells is involved in impaired
T-cell–mediated tumor rejection and supports tumor
angiogenesis.39,40
PDGFRB is a tyrosine kinase inhibitor involved in
angiogenesis, autocrine stimulation of tumor cells, and
regulation of interstitial fluid pressure.41-43 Only a few
reports have analyzed the expression of PDGFRB in
PanNETs, and all indicated that functioning PanNETs
and NFPanNETs overexpress PDGFRB mRNA and pro-
tein.35,41,44 In the current study, we demonstrated that
the VHL NFPanNET genotype expresses the highest
PDGFRB mRNA and protein levels compared with the
MEN1 and sporadic genotypes and that PDGFRB pro-
tein staining is mostly positive in the VHL stroma.
PDGFRB in tumor stroma is important for regulating
interstitial fluid pressure, and inhibition of this protein
may allow for greater uptake of other chemotherapy
drugs.43 Thus, we propose that NFPanNETs with altera-
tions in the VHL promoter or mutations in the VHL gene
may be particularly susceptible to PDGFRB antagonist
treatment.
Because the tyrosine kinase inhibitors currently used
for treatment of advanced PanNETs can be associated
with the development of resistance over time, a combina-
tion of antiangiogenic and immune-based treatment
could be beneficial in tumors that express high levels of
angiogenic and immune infiltrating cells. Therefore,
based on the current results, we believe that VHL-
associated, locally advanced, and metastatic NFPanNETs
may be especially good candidate for such combination
therapies.
Singhi and colleagues analyzed the expression of
LEF1 in pancreatic neoplasms and observed no expression
in 44 well differentiated neuroendocrine tumors.45 This
contradicts our findings. It is unclear whether the Pan-
NET samples studied were all sporadic and had no altera-
tions in the VHL gene or VHL expression levels. If it is
further confirmed that the transcription factor LEF1 is
upregulated only in VHL NFPanNETs, then it poten-
tially could be targeted by the currently available small-
molecule inhibitors used in chronic lymphocytic
leukemia.46
CDK inhibitor 1B (CDKN1B [p27Kip1]) is an
enzyme inhibitor, and we observed that it was under-
expressed in the MEN1 NFPanNET genotype.
CDKN1B is considered a tumor suppressor because it
functions as a cell-cycle regulator, by in part preventing
the activation of the cyclin D-CDK4 complex. Its inacti-
vation can be accomplished post-transcription by the
activation of several pathways, including the Ras-
mitogen–activated protein kinase pathway, which is
upregulated in MEN1 NFPanNETs, as was previously
reported.47
In this study, we also demonstrated that CDK4 and
CDK6 gene expression was higher in the MEN1 NFPan-
NET genotype. Tang and associates analyzed the
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expression of CDK4 and CDK6 in functioning PanNETs
and NFPanNETs and reported high CDK4 expression
levels and increased copy numbers of CDK4 and CDK6.
They also observed that the human PanNET cell line
QGP1 was inhibited in a xenograft mouse model by the
CDK4/CDK6 inhibitor PD0332991.48 In another study,
knockdown of CDK6 enhanced glioma sensitivity to the
chemotherapeutic temozolomide, which has demon-
strated effectiveness in treating PanNETs.49,50 Inhibitors
of CDK6 are currently in clinical trials for other malig-
nancies; therefore, understanding which subset of NFPan-
NETs could benefit from CDK4/CDK6 inhibition and
potentially from enhancing temozolomide efficacy with
CDK6 inhibitors would be of interest and should be
investigated further.
The current study has several limitations. We used
human islets cells for some of the comparisons, and these
cells were not sorted to distinguish the specific cell type
population. This may have influenced the results from
comparing NFPanNETs with NICs, because it is gener-
ally believed that NFPanNETs originate from a single cell
type. Newer methods to isolate single-cell populations
have recently been described and could be applied in the
future.51 Furthermore, although we confirmed the over-
expression of LEF1, CDK4, CDK6, NOTCH3, RYR3,
and IGF2 in an independent cohort of NFPanNETs, we
cannot reliably determine that these genes can segregate
NFPanNETs by genotype, because this particular valida-
tion set does not have data on mutations in the MEN1 or
VHL genes. Additional future studies will be needed for
this purpose. Finally, although we validated highly differ-
entially expressed genes that may have biologic signifi-
cance and could be targeted for therapy at the protein
level (such as PDGFRB), we cannot be certain that this
applies to all of the differentially expressed genes identi-
fied in the current study.
In summary, we have demonstrated genotype-
specific differences in mRNA expression patterns in spo-
radic NFPanNETs, VHL-associated NFPanNETs, and
MEN1-associated NFPanNETs; and the results suggest
that genotype-specific and subtype-specific activation of
pathways may contribute to NFPanNET tumorigenesis.
These findings implicate specific genes and pathways that
could be exploited to identify new diagnostic or therapeu-
tic pathways and allow for subtype-specific treatments of
NFPanNETs in the future.
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